Pfizer Announces New Multi-Year Cost Optimization Plan to Enhance Operational Efficiency and Portfolio Focus

Intelligent Finance News learned that PfizerCompanyWednesday stated that the company has launched a new multi-yearPlannedPlan to reduce costs, while striving to recover from the rapid decline in the COVID-19 business.In a securities filing, the pharmaceutical giant said that the first phase of its new plan focuses on improving operational efficiency and is expected to save the company about 15 by the end of 2027.Billion US dollars.One-time costs associated with the early stages of layoffs are estimated to be approximately $1.7 billion, including severance payments for an undisclosed number of laid-off employees.The companyMost of these costs are expected to be recorded this year.

Pfizer announced another $4 billion cost-cutting plan last year as demand for its COVID-19 vaccine and oral drug Paxlovid plummeted.

A spokesperson for Pfizer, Inc. said the plan would also involve "portfolio enhancements" and changes to the company’s manufacturing and supply network. In a statement, the spokesperson said: "The plan will focus on streamlining our ways of working, reducing complexity, and improving the productivity of Pfizer's global supply."

Pfizer added in the document: "Given the complexity of manufacturing and the long lead times required to make changes, this will be a multi-phase effort."

Pfizer’s stock price fell nearly 50% in 2023, making it the worst-performing pharmaceutical stock last year, as the company is currently trying to boost investor sentiment. This decline wiped out more than $100 billion of Pfizer's market value. With a significant drop in demand for COVID-19 products last year, Pfizer also disappointed Wall Street by launching a new RSV vaccine and a twice-daily weight-loss drug that underperformed in clinical trials, with its initial 2024 forecast falling short of expectations.

But Pfizer's first-quarter revenue and adjusted profit, announced earlier this month, exceeded expectations, and the company raised its full-year earnings forecast, delighting investors. The pharmaceutical giant said its new profit guidance reflected "confidence" in its business and its ability to cut costs.

Pfizer CEO said on the earnings call on May 1: "We are cautiously optimistic about this year." The company's stock closed up 6% that day. Since then, Pfizer's stock has risen nearly 14%.